Gonadorelin (GnRH)
Natural GnRH — stimulates or suppresses depending entirely on dosing rhythm.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Gonadorelin (GnRH)
Gonadorelin is the natural gonadotropin-releasing hormone decapeptide, which triggers LH and FSH release from the anterior pituitary. The single most important thing to understand about it is direction: GnRH is normally released in pulses, and pulsatile delivery maintains gonadotropin output, whereas continuous or frequent exposure down-regulates the GnRH receptor and reduces LH and FSH. The approved human product, Lutrepulse, respected that biology by delivering 5mcg intravenously every 90 minutes through a pump — in a 109-woman trial for hypothalamic amenorrhea it produced ovulation in 91–96% of patients. Gonadorelin's circulating half-life is only a few minutes, so a once- or twice-daily subcutaneous injection does not reproduce that regimen. It is widely used in the research market as a stimulating agent on the assumption that any GnRH raises LH, which is not how the receptor behaves. Both human products are gone: the human Factrel diagnostic formulation and Lutrepulse were discontinued. The FDA-approved Factrel marketed today is a veterinary product, indicated for ovarian follicular cysts in dairy and beef cattle.
Key Benefits
- The natural GnRH sequence rather than a modified analogue
- Pulsatile delivery induced ovulation in 91–96% of women in the Lutrepulse trial
- Very short half-life, so effects do not accumulate
- Used diagnostically to separate hypothalamic from pituitary causes of hypogonadism
Set a goal (top of the page) to see how Gonadorelin (GnRH) scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Headache
- Nausea and abdominal discomfort
- Flushing
- Injection site reactions
- Paradoxical suppression of LH and FSH if dosed continuously or too frequently
- Ovarian hyperstimulation and multiple pregnancy risk in the approved fertility use
Legal & Regulatory Status
The human formulations (Factrel diagnostic, Lutrepulse) are discontinued. The FDA-approved Factrel sold today is a VETERINARY product for ovarian follicular cysts in cattle — there is no currently marketed FDA-approved gonadorelin for human use.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- FACTREL (gonadorelin hydrochloride) injection — current FDA label; veterinary indication (DailyMed)
- Efficacy and safety of intravenous pulsatile GnRH: Lutrepulse for injection (PMID 2122733)
- Ovulation induction with pulsatile intravenous GnRH (PMID 3908673)
- Pulsatile GnRH administration — diagnostic and therapeutic indications (PMID 2143826)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
Prices at quality-checked sources · as of August 2026 (8 days ago)
- 2mg $37.605mg $93.98
Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.
Builds a working set shared across the stack builder, calculator, scheduler and compare.